• Aman kumar


Updated: Sep 5, 2020

It's proud movement for INDIA that AIIMS delhi has started first covid-19 vaccine human trail .

let's hope for best results.Over 2,000 volunteers have enrolled for the first phase of human clinical trial of Covaxin. India's COVID-19 vaccine has started the human trial on July 15. The vaccine has been developed by the Hyderabad-based pharmaceutical company Bharat Biotech in collaboration with National Institute of Virology (NIV) and Indian Council of Medical Research (ICMR)

  • AIIMS-Delhi is is among the 12 sites selected by ICMR for phase I and II trial of Covaxin

  • A Delhi resident took the first dose of India's COVID-19 vaccine candidate at AIIMS today

  • 30-year-old gets shot, no side effects so far.

{1] The Drug Controller General of India (DCGI) earlier approved two vaccines — one developed by the Bharat Biotech and another one by ZydusCadila to go in for the first and second phase of human clinical trials.The Drug Controller General of India has also give approval for cheapest price for vaccine.

{2] At least seven Indian pharmaceutical companies are working on the coronavirus vaccine India. These firms are Bharat Biotech, Serum Institute, Zydus Cadila, Panacea Biotec, Indian Immunologicals, Mynvax and Biological E.

{3] The Drug Controller General of India (DCGI) earlier approved for cheapest rate of covid vaccine .The price of Brinton pharma medicine Faviton one tablet is INR 59 rupees and jenburkt pharma medicine Favivent one tablet is INR 39 rupees.

{4] On how Covaxin works, Bharat Biotech said, “Once the vaccine is injected into a human, it has no potential to infect or replicate, since it is a killed virus. It just serves to the immune system as a dead virus and mounts an antibody response towards the virus."

{5] The trial has also started at Nizams Institute of Medical Sciences, Hyderbad; Post-Graduate Institute (PGI) of Medical Sciences in Rohtak; AIIMS Patna; Institute of Medical Sciences and SUM (IMS & SUM) Hospital in Bhubaneswar among others.

{6] A Delhi resident took the first dose of India's COVID-19 vaccine at AIIMS. "The first dose of 0.5 ml intramuscular injection was given to him around 1.30 pm. No immediate side-effects have been observed so far. He was under observation for two hours and will be monitored for the next seven days," Dr Sanjay Rai, Professor at the Centre for Community Medicine at AIIMS said.

{7] The first volunteer was screened two days ago, according to reports by the news agency PTI{5] "In the first phase we see the safety of the vaccine which is of primary importance and the dose range is also calculated," said AIIMS Director Dr Randeep Guleria.

{8] Covaxin has been derived from a strain of the novel coronavirus isolated by the National Institute of Virology in Pune. Bharat Biotech developed an “inactivated" vaccine at its high-containment facility at Genome Valley in Hyderabad.

{9] There are three formulations of the COVID-19 vaccine candidate. Each subject will be given any one of the formulation in two doses two weeks apart. The first 50 will get the lowest strength dose of the vaccine. If it is found to be safe in them, then it will be given to another 50 patients in high doses, Dr Rai told PTI.

{10] The human trials of coronavirus vaccine have initiate at Goa's Redkar Hospital this week, confirmed state chief minister Pramod Sawant. "Human trials of Covaxin, an indigenously developed vaccine for COVID-19, has begun at Redkar Hospital in Goa. This is a testimony of India's immense potential in healthcare innovation. My best wishes to the entire team working on Covaxin," Sawant earlier tweeted.

{11] India has a fantastic "vaccine capability" and it would play a crucial role in the partnerships the UK is building on COVID-19 vaccine development and manufacturing, the new British High Commissioner earlier said.

SOUCRCE :- AIIMS delhi ,news etc

22 views0 comments



  • Facebook

copyright© 2020-2021 

Subscribe to Blog via Email
Receive all our future posts instantly in your inbox.
Enter your email to enroll..